Cellectis SA (CLLS) AI Stock Analysis

Compare

948 Followers

Top Page

Cellectis SA

(NASDAQ:CLLS)

Rating:61Neutral

Price Target:

$2.50

▼(-15.25%Downside)

Cellectis SA's stock score is primarily driven by its strong technical performance, reflecting current market optimism and momentum. Despite this, the company's financial performance is hampered by profitability challenges, and the valuation presents significant risks due to ongoing losses. The absence of earnings call insights and corporate events means these factors did not influence the score.

Positive Factors

Financial Position

Management anticipates that the cash position is strong, with approximately $246 million in cash, cash equivalents, restricted cash, and fixed-term deposits.

Operational Progress

Strong demand for trial entry should facilitate enrollment speed for UCART20x22.

Strategic Partnerships

Cellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AstraZeneca.

Negative Factors

Data Requirements

Durability data in larger cohorts is needed to have confidence in the assets.

Financial Performance

Net loss per share was ($0.18) versus consensus of ($0.15).

Cellectis SA (CLLS) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$207.75M

Dividend YieldN/A

Average Volume (3M)221.69K

Price to Earnings (P/E)―

Beta (1Y)3.23

Revenue Growth825.97%

EPS Growth38.32%

CountryUS

Employees216

SectorHealthcare

Sector Strength39

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.24

Shares Outstanding72,093,636

10 Day Avg. Volume406,413

30 Day Avg. Volume221,688

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.05

Enterprise Value/Revenue-0.22

Enterprise Value/Gross Profit-0.35

Enterprise Value/Ebitda0.29

Forecast

1Y Price Target

$3.50

Price Target Upside18.64% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Cellectis SA Business Overview & Revenue Model

Company DescriptionCellectis SA (CLLS) is a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR-T cells. Operating primarily in the biotechnology sector, Cellectis uses its proprietary gene-editing technologies to create targeted cancer treatments. The company's core products include off-the-shelf CAR-T cell therapies aimed at addressing various types of cancers.

How the Company Makes MoneyCellectis makes money through the development and commercialization of its proprietary CAR-T cell therapies. The company's revenue model includes generating income from product sales, licensing agreements, and strategic collaborations with other biotechnology and pharmaceutical companies. Cellectis enters into partnerships for the development and commercialization of its therapies, which can include upfront payments, milestone payments, and royalties on sales. Additionally, Cellectis may receive funding from research grants and public or private investments that support its development efforts.

Cellectis SA Earnings Call Summary

Earnings Call Date:Aug 04, 2025

(Q4-2024)

% Change Since: 95.36%|

Next Earnings Date:Nov 10, 2025

Earnings Call Sentiment Positive

The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.

Q4-2024 Updates

Positive Updates

Strategic Collaboration with AstraZeneca

Cellectis announced the start of three research and development programs under its collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca also completed an additional equity investment of $140 million in Cellectis.

Financial Stability and Cash Runway

Cellectis drew down the last tranches of a €40 million credit facility with the European Investment Bank and reported that their cash runway allows operations to be funded into mid-2027. As of December 31, 2024, the company had $264 million in cash, cash equivalents, and fixed term deposits, up from $156 million the previous year.

FDA and European Commission Designations

The FDA granted Orphan Drug Designation and Rare Pediatric Disease status to UCART22, and the European Commission granted Orphan Drug Designation for the treatment of relapse or refractory acute lymphoblastic leukemia.

Advancements in Clinical Trials

Cellectis expects to present Phase 1 data for UCART22 and UCART20x22 in 2025, with plans to open Phase 2 studies in Q4 2025. Recruitment for the BALLI-01 study evaluating UCART22 has progressed well.

Positive Financial Performance

Thanks to the AstraZeneca collaboration, $47 million were received up to year-end 2024, including $22 million from development milestones.

Promising Innovation in CAR T Strategies

Cellectis showcased promising CAR T strategies utilizing TALEN gene editing technology, with preclinical data presented at major conferences and publications in scientific journals.

Negative Updates

Servier Arbitration

There is ongoing arbitration with Servier, although specific details remain undisclosed.

Challenges in Patient Enrollment

Enrollment for the NATHALI-01 study of UCART20x22 in relapsed or refractory non-Hodgkin's lymphoma continues, but specific challenges or delays in enrollment were not detailed.

Company Guidance

In the recent Cellectis earnings call for fiscal year 2024, the company provided guidance on several key metrics. Cellectis announced that its cash runway is now extended to mid-2027, thanks to an additional equity investment of $140 million from AstraZeneca, which now owns approximately 44% of Cellectis' share capital and 30% of voting rights. The company also reported that it received $47 million under its collaboration with AstraZeneca, including $25 million upfront and $22 million from development milestones. Cellectis' cash, cash equivalents, and financial assets increased to $264 million as of December 31, 2024, compared to $156 million in the previous year. This increase is attributed to the equity investment, $20 million from the European Investment Bank credit facility, and revenue from partnerships, offset by operational expenses. The company expects to present Phase 1 data for UCART22 and UCART20x22 in 2025 and continues to advance its core clinical trials and collaboration with AstraZeneca.

Cellectis SA Financial Statement Overview

Summary

Cellectis SA demonstrates mixed financial health with some strengths in liquidity and cash management but ongoing challenges in profitability and revenue consistency. The balance sheet indicates a stable but declining equity position, while cash flow improvements provide a positive outlook amid persistent net losses.

Income Statement

Neutral

The company shows a fluctuating revenue trend, with a significant decline from 2021 to 2023, followed by a recovery in 2024 and TTM. Gross profit margin is relatively stable but net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.

Balance Sheet

Neutral

The balance sheet reveals a moderate debt-to-equity ratio, suggesting manageable leverage. The equity ratio has been declining, which might indicate increasing liabilities relative to assets. Despite this, the company maintains a solid cash position, which can be advantageous for liquidity.

Cash Flow

Positive

Positive developments in cash flow are noted, with operating cash flow turning positive in recent periods. The free cash flow growth is encouraging, although the company has historically faced negative free cash flows. The ratio of operating cash flow to net income is favorable, highlighting efficient cash management despite net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	41.51M	755.00K	19.17M	73.95M	73.95M
Gross Profit	21.63M	18.00K	17.40M	37.67M	37.67M
EBITDA	-15.84M	-92.64M	-76.38M	-86.46M	-34.68M
Net Income	-36.76M	-101.06M	-98.69M	-86.28M	-72.57M
Balance Sheet
Total Assets	383.54M	334.27M	261.22M	382.08M	469.47M
Cash, Cash Equivalents and Short-Term Investments	260.31M	203.81M	97.70M	186.13M	268.24M
Total Debt	91.46M	92.85M	82.85M	102.24M	111.30M
Total Liabilities	252.51M	249.57M	135.28M	145.60M	160.63M
Stockholders Equity	131.03M	84.69M	117.97M	221.29M	275.57M
Cash Flow
Free Cash Flow	19.15M	-25.82M	-89.89M	-124.31M	-126.52M
Operating Cash Flow	22.99M	-24.75M	-87.44M	-104.56M	-80.26M
Investing Cash Flow	-102.81M	-15.51M	-2.76M	7.28M	-54.34M
Financing Cash Flow	89.11M	82.86M	1.15M	47.52M	27.32M

Cellectis SA Technical Analysis

Technical Analysis Sentiment

Positive

Last Price2.95

Price Trends

50DMA

1.72

Positive

100DMA

1.56

Positive

200DMA

1.64

Positive

Market Momentum

MACD

0.31

Negative

RSI

69.25

Neutral

STOCH

70.62

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLLS, the sentiment is Positive. The current price of 2.95 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 1.72, and above the 200-day MA of 1.64, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 69.25 is Neutral, neither overbought nor oversold. The STOCH value of 70.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLLS.

Cellectis SA Risk Analysis

Cellectis SA disclosed 102 risk factors in its most recent earnings report. Cellectis SA reported the most risks in the "Tech & Innovation" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Cellectis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	61 Neutral	$207.75M	―	-58.55%	―	825.97%	38.32%
FDMT	57 Neutral	$297.40M	―	-32.97%	―	―	―
EDIT	56 Neutral	$204.26M	―	-140.82%	―	-48.37%	-44.70%
CRBU	52 Neutral	$181.36M	―	-52.76%	―	-70.31%	-11.68%
Sector *	51 Neutral	$7.38B	0.34	-69.01%	2.37%	16.35%	0.39%
NKTX	39 Underperform	$150.43M	―	-26.10%	―	―	30.76%
VOR	33 Underperform	$262.41M	―	-125.43%	―	―	2.98%

* Healthcare Sector Average

Performance Comparison

CLLS

Cellectis SA

2.95

0.91

44.61%

EDIT

Editas Medicine

2.44

-2.29

-48.41%

NKTX

Nkarta

2.12

-3.59

-62.87%

FDMT

4D Molecular Therapeutics

6.42

-8.71

-57.57%

VOR

Vor Biopharma

2.10

1.30

162.50%

CRBU

Caribou Biosciences

1.95

-0.01

-0.51%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 02, 2025